CTOs on the Move

SurgiMa

www.surgima.com

 
SurgiMa is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.surgima.com
  • 809 San Antonio Rd Ste 1
    Palo Alto, CA USA 94303
  • Phone: 650.494.0210

Executives

Name Title Contact Details

Similar Companies

Pacesetter Medical

Pacesetter Medical is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

medical supply net

medical supply net is a San Dimas, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immucor

For more than 30 years, Immucor has been a proud partner to thousands of hospitals, reference laboratories and donor centers. We remain focused on continuing to innovate as we work to advance the science of transfusion and transplantation diagnostics. We are guided by our corporate Mission and Values. We strive to create a world where anyone, anywhere in need of blood or an organ gets the right blood or organ that is safe, accessible and affordable. We will be guided by our Core Values of Respect, Integrity, Teamwork and Achievement. In doing so, we will: • strive to achieve the highest quality products and solutions; • bring forth and pursue innovations that advance patient safety; • honor our customers with the highest level of service.

Graymark Healthcare

Graymark Healthcare, Inc. (Graymark) is a diversified healthcare services company, which conducts business in two operating segments, Sleep Management Solutions and Apothecary. Sleep Management Solutions (SMS), is a provider of care management solutions

MY01

MY01 is a state-of-the-art medical device geared towards aiding in the detection of Compartment Syndrome (CS); a limb-threatening muscle condition that occurs within 48 hours following trauma. Currently, ACS is diagnosed based on subjective and unreliable outcomes like pain (known as 6 P`s), which when present cannot confirm the diagnosis in time for effective intervention. This leads to increased complications (muscle necrosis/amputation) and costs the US healthcare system more than $2.25 B annually. MY01 is capitalizing on a proven correlation between sustained increase in Intramuscular pressures and ACS for objective, early diagnosis. MY01 operationalizes muscular pressure monitoring into a simple, accurate single-use device. MY01. The simple solution to a dangerous problem.